Skip to content

Efficacy of Physiotherapist-supervised Rehabilitation After Proximal Humerus Fracture

Efficacy of Physiotherapist-supervised Rehabilitation After Two-part Proximal Humerus Fractures Treated Non-operatively. A Randomised Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03498859
Enrollment
70
Registered
2018-04-17
Start date
2018-04-24
Completion date
2022-01-25
Last updated
2023-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Proximal Humeral Fracture

Keywords

Rehabilitation

Brief summary

This study investigates the efficacy of physiotherapist-supervised training once per week during 10 weeks compared to home-based training during 10 weeks, after proksimal humerus fracture.

Detailed description

Proximal humerus fracture is the third most common fracture in elderly people after hip and colles fracture, and are often caused by fall and osteoporosis. These fractures are highly related to morbidity and mortality among elderly people and consumes considerably health care resources. More than 70% of the proximal humerus fracture patients are over 60 years of age and 75% are female. Only sparse evidence reveals to what extend the patients need rehabilitation and how it should be implemented in the treatment strategy. In Denmark as well as in Finland the rehabilitation after proximal humerus fractures takes place in local centers in the municipalities, and the rehabilitation offered to the patients varies significantly. Currently in Denmark there are no national clinical guidelines to support the rehabilitation strategy.

Interventions

OTHERPhysiotherapist-supervised training

The intervention is physiotherapist-supervised training once per week during 10 weeks.

The intervention is home-based training during 10 weeks

Sponsors

Tampere University Hospital
CollaboratorOTHER
Oslo University Hospital
CollaboratorOTHER
Regionshospitalet Viborg, Skive
CollaboratorOTHER
University of Aarhus
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No

Inclusion criteria

•Low energy proximal humeral displaced (more than 5mm or 30 degrees) two-part fracture where fracture line emerges through the surgical (or anatomical) neck, treated non-operatively

Exclusion criteria

* Refuse to participate in the study * Younger than 60 years old * Non-independent * Demented * Does no understand written and spoken guidance in local language * Pathological fracture or previous fracture in the same proximal humerus * Other operational injuries in the same upper limb * Major nerve injury (e.g. Complete radialis- or delta palsy) * Open fracture * Multi-trauma patient * Fracture dislocation or head splitting fracture * Undisplaced fracture * Isolated tuberculum fracture * Fracture has no precondition to ossify by conservative treatment (no bony contact between fracture parts or the humeral shaft is in contact with the articular surface) * Treating surgeon considers patient unsuitable to attend the study on medical basis

Design outcomes

Primary

MeasureTime frameDescription
The Disability of the Arm, Shoulder and Hand (DASH)Measured at 3 months after fracturePatient reported outcome measure of physical function in the upper extremity. Measures on a 0-100 scale, where a higher score indicates greater disability. The scores will be compared between the 2 groups

Secondary

MeasureTime frameDescription
The Disability of the Arm, Shoulder and Hand (DASH)Measured at baseline and after 12 monthsPatient reported outcome measure of physical function in the upper extremity. Measures on a 0-100 scale, where a higher score indicates greater disability. The scores will be compared between the 2 groups
Constant Murley Shoulder ScoreMeasured after 3 and 12 months.Subjective and objective measurement of the shoulder function. Measures on a 0-100 scale, where a lower score indicates greater disability. The scores will be compared between the 2 groups
15-dimentional health-realted quality of life instrument (15D)Measured at baseline, after 3 and 12 monthsPatient reported outcome measure of health related quality of life. A set of utility or preference weights is used to generate the 15D score (single index number) on a 0-1 scale, where a higher score indicates a poor health related quality of life. The scores will be compared between the 2 groups
Generel Self-Efficacy scaleMeasured at baseline, after 3 and 12 monthsPatient reported outcome measure. Measures on a 10-40 scale, where a higher score indicates a higher degree of self-efficacy. The scores will be compared between the 2 groups. Also the correlation with DASH scores will be investigated
Accelerometer based activity in the upper extremityMeasured at 3 and 12 monthsThe patient is wearing a censor above the elbow on both arms, that measures the level of upper extremity activity for three consecutive days. It measures the number of movements under and above shoulder hight and classify them into either high or low intensity movements. The asymmetry between the fractured and the healthy arm will be estimated and compared between the groups.
Pain catastrophizing ScaleMeasured at baseline, after 3 and 12 monthsPatient reported outcome measure. Measures on a 0-53 scale, where a higher score indicates a higher levels of pain catastrophizing thinking. The scores will be compared between the 2 groups. Also the correlation with DASH scores will be investigated

Other

MeasureTime frameDescription
Follow up of the declinersMeasured at baseline and 3 monthsPatients declining to participate in the randomised trial will be invited to follow up visits, consisting of x-rays and identical questionnaires as used in the RCT
Cost-effectivenessAfter 12 monthsA cost-effectiveness analysis (QALY) of the two training modalities will be performed and a ratio will be estimated.

Countries

Denmark, Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026